Foxo Technologies provides shareholder letter from Interim CEO

FOXO Technologies provides a shareholder letter from Mark White, Interim CEO of FOXO, on what has been achieved in 2024 and what is planned for the remainder of 2024 and beyond. “The Company began 2024 with a continued focus on commercializing its epigenetic technology while, at the same time, exploring acquisition opportunities that would accelerate growth, revenue and synergies to expand our business in the health care and well-being sectors… The Company expanded its financial management capabilities in the second quarter of 2024 and is confident it will remain consistently compliant with SEC reporting requirements going forward… …We have a number of targets to accomplish in the last quarter of 2024. We will shortly announce a date for our Annual General Meeting; We remain focused to ensure the Company meets the continued listing requirements of NYSE American.; We are actively in discussion with debtholders and other parties to address legacy debts and liabilities.; We are seeking new capital, some of which is already committed, to expand our recently acquired businesses, pursue acquisitions, and launch and deliver our epigenetic technology to the marketplace.; We will update our shareholders as we progress and are in process of updating our website and online presence to better reflect our expanded business as a result of 2024 accomplishments.